Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

China approves Novartis' multiple sclerosis treatment Mayzent

FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo

Chinese regulators have approved Novartis' Mayzent to treat relapsing multiple sclerosis in adults, the Swiss drug maker said in a statement on Saturday.

Other drugs approved by China's National Medical Products Administration to treat MS include Novartis' Gilenya, Bayer's Betaferon and Sanofi's Aubagio. China has an estimated 30,000 patients with MS.

(Reporting by Roxanne Liu and Kevin Yao in Beijing; Editing by Edwina Gibbs)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.